Gyn Onc Landmark: GOG-261 (Uterine Carcinosarcoma) скачать в хорошем качестве

Gyn Onc Landmark: GOG-261 (Uterine Carcinosarcoma)

GOG-261 Clinical Trial Hypothesis The study hypothesized that paclitaxel plus carboplatin would provide non-inferior overall survival (OS) compared to paclitaxel plus ifosfamide in patients with recurrent or metastatic uterine or ovarian carcinosarcoma, with the potential for improved tolerability and reduced toxicity. Inclusion Criteria Patients with histologically confirmed uterine or ovarian carcinosarcoma Recurrent, persistent, or metastatic disease No prior chemotherapy for metastatic disease (except for adjuvant therapy, if completed more than six months prior) Primary Endpoints Overall survival (OS): To determine whether paclitaxel-carboplatin is non-inferior to paclitaxel-ifosfamide Progression-free survival (PFS): To compare time to disease progression or death between the two regimens Toxicity and Adverse Events: To assess safety and tolerability of both regimens Conclusion GOG-261 demonstrated that paclitaxel plus carboplatin was non-inferior to paclitaxel plus ifosfamide in terms of overall survival. Additionally, the carboplatin-containing regimen was associated with fewer toxicities, making it a more tolerable and preferable treatment option for patients with uterine and ovarian carcinosarcoma. These findings established paclitaxel-carboplatin as the new standard of care for this patient population.